文献速递临床试验与 GCP

一项针对创伤后应激障碍的雾化大麻小型临床试验:结果提示性及未来研究方向

A small clinical trial of vaporized cannabis for PTSD: suggestive results and directions for future study.
PubMed 文献 · Trials · 2023-09-09

该随机安慰剂对照交叉试验评估商用化学型大麻雾化给药对创伤后应激障碍的疗效,仅5人完成试验,无法分析安慰剂效应。结果发现大麻治疗创伤后应激障碍具有中等大小的个体内效应,呈阳性趋势;高患者需求使未来研究成为必要。

要点

  • 该随机安慰剂对照交叉试验仅5人完成,无法分析安慰剂效应。
  • 结果发现大麻治疗创伤后应激障碍具有与中等大小个体内效应一致的阳性变化。
  • 结果呈阳性趋势且患者需求高,使未来大麻治疗创伤后应激障碍的研究成为必要。

核心结论

  • 结果发现大麻治疗创伤后应激障碍具有与中等大小个体内效应一致的阳性变化。
  • 阳性趋势结果和高患者需求使未来大麻治疗创伤后应激障碍的研究成为必要。

研究设计与样本

  • 研究设计为随机安慰剂对照交叉研究,设三种条件,但仅5人完成试验。
  • 研究评估一种商用化学型大麻经雾化给药的效果。

主要发现

  • 仅5人完成试验,无法分析安慰剂效应。
  • 结果发现大麻治疗创伤后应激障碍具有与中等大小个体内效应一致的阳性变化。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 仅5人完成试验,无法分析安慰剂效应。
  • 近期评估大麻治疗创伤后应激障碍临床疗效的尝试结果不确定,且研究药物的不良特征限制了普遍性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The last few decades have seen increasing interest in the use of cannabis for post-traumatic stress disorder (PTSD). Recent attempts to evaluate the clinical efficacy of cannabis for PTSD were inconclusive and generalizability was limited by undesirable features of the study drug. The present clinical trial evaluated the effects of a commercially available chemovar that was delivered by vaporization. The study was designed as a randomized placebo-controlled cross-over study with three conditions; however, only five individuals completed the trial, and analysis of the placebo effect was not possible. Results identified positive changes consistent with medium-sized within-subject effects for cannabis in the treatment of PTSD. Positive trending results and high patient need mandate future studies of cannabis for the treatment of PTSD.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Walsh Z, Mitchell I, Crosby K, et al. A small clinical trial of vaporized cannabis for PTSD: suggestive results and directions for future study. Trials. 2023. PMID: 37689680. doi:10.1186/s13063-023-07543-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。